Seres Therapeutics, Inc. · NASDAQ:MCRB
Seres Therapeutics — Investor Presentation (January 2024)
27 slides from Seres Therapeutics's investor presentation, Jan 9, 2024
Slide 1: Seres Therapeutics Investor Presentation
January 10, 2024 Seres Therapeutics Investor Presentation Exhibit 99.1
Slide 2: Forward Looking Statements
Some of the statements in this presentation constitute “forward looking statements” under the Private Securities Litigation Reform Act of 1995, including, but not limited to the anticipated supply and degree of market acceptance of VOWST; the potential for microbiome therapeutics to protect against
Slide 3: January Updates
January Updates Drove significant broad demand with 2,015 new patient starts since commercial launch in June SER-155 SER-155 received US FDA Fast Track designation; Phase 1b clinical data expected Q3 2024 | Seres Therapeutics, Inc. © 2024
Slide 4: The Seres Story: Maximizing the Potential of the Microbiome
The Seres Story: Maximizing the Potential of the Microbiome Leading with VOWST™ 1 Company Profile: Leader in microbiome therapeutics with the first FDA approved orally administered therapeutic VOWST: Exceptional clinical profile meeting high unmet medical need and demonstrating early favorable adopt
Slide 5: Founded in 2011, Seres' Mission is to Transform Lives with Microbiome Therapeutics
Founded in 2011, Seres' Mission is to Transform the Lives of Patients Worldwide with Revolutionary Microbiome Therapeutics Encapsulated consortia of commensal bacteria designed to target multiple disease-relevant pathways simultaneously Bacterial Consortia Orally-formulated, using current Good Manuf
Slide 6: VOWST Became the First FDA Approved Oral Microbiota-Based Therapeutic
In April 2023, VOWST™ Became the First FDA Approved Orally Administered Microbiota-Based Therapeutic VOWSTTM is indicated to prevent the recurrence of C. difficile infection (CDI) in individuals 18 years of age or older following antibacterial treatment for recurrent CDI (rCDI). | Seres Therapeutics
Slide 7: Company Profile: Leader in microbiome therapeutics
Company Profile: Leader in microbiome therapeutics with the first FDA approved orally administered microbiota-based therapeutic 2 VOWST: Exceptional clinical profile meeting high unmet medical need and demonstrating early favorable adoption 3 SER-155 Ongoing Phase 1b Study: Expanding proven novel te
Slide 8: Preventing rCDI is an Important Opportunity That Can Save Lives
Preventing rCDI is an Important Opportunity That Can Save Lives High probability of recurrence >20%, usually within 1-2 weeks after completion of antibiotic therapy Symptoms include colitis and severe, watery diarrhea with up to 15 bowel movements a day Spore-forming, toxin-producing, gram-positive,
Slide 9: Compelling Phase 3 Study Results
Compelling Phase 3 Study Results Time point SER-109 (N =89) Placebo (N =93) Relative risk (95%CI) p-value (p1/p2) n (%) of recurrences n (%) of recurrences Week 8 11 (12.4) 37 (39.8) 0.32 (0.18-0.58) <0.001 / <0.001 TRIAL DESIGN Multiply recurrent C. difficile patients (n=182) All subjects treated w
Slide 10: VOWST Offers a Highly Attractive Product Profile
VOWST Offers a Highly Attractive Product Profile Well-tolerated in Phase 3 clinical studies. The most common adverse reactions (reported in ≥5% of participants) were abdominal distension (31.1%), fatigue (22.2%), constipation (14.4%), chills (11.1%), and diarrhea (10.0%) Oral dosing - 4 capsules onc
Slide 11: HCP Enthusiasm for VOWST Driven by Desire to Prevent Recurrences
HCP Enthusiasm for VOWST Driven by Desire to Prevent Recurrences and Limitations of Current Options Top 5 rCDI Treatment Goals % Ranked in Top 3 Prevention of recurrences Prevention of morbidity / mortality Restoring patient QoL Symptom relief Restoration of gut microbiome Preventing subsequent recu
Slide 12: Launch Priority
Launch Priority ~70% of rCDI patients complete antibiotic treatment as an outpatient; VOWST is dispensed and administered in the outpatient setting for these patients Prioritizing Patients Completing Treatment in the Outpatient Setting and Reimbursed via the Outpatient Pharmacy Benefit Initiates tre
Slide 13: VOWST Field Teams Deployed from Nestle Health Science
Prioritize top volume and early adopting HCPs: 150-person GI sales force GI sales force covers 85% of GI practices for current inline Nestle product, ZENPEP Average 10 years industry experience & 5 years in GI Drove ZENPEP® acceleration over last 3 years Prioritize ~300 top HCOs: 20-person hospital
Slide 14: Strong Initial VOWST Uptake Since June 2023 Launch
Strong Initial VOWST Uptake Since June 2023 Launch Data below from June through December 31, 2023, as provided by Nestlé Health Science Patient Enrollment Forms New Patient Starts Net Sales (unaudited) 2,833 Incl. 1,322 in Q4 2,015 Incl. 1,082 in Q4 $19.6M Incl. $10.4M in Q4 Enrollment forms were su
Slide 15: Expect HCP Use of VOWST to Broaden with Product Experience
Expect HCP Use of VOWST to Broaden with Product Experience Initial Trial Patient Types “People with comorbidities have a bigger likelihood of recurrence but sometimes you just can't predict who will have one. But if cost isn't an issue, I'll give it to everyone, why not.” – GI “The first patient I'd
Slide 16: Aggressively Managing Positive Experience Early for Long Term Success
Aggressively Managing Positive Experience Early to Set Up VOWST for Long Term Success Patient Access Product Choice LAND First 12 months EXPAND >12 months Implement payer policies as quickly as possible to ease access to treatment Access programs to support positive early experience Ensure high qual
Slide 17: Well Positioned to Supply Commercial Demand
Well Positioned to Supply Commercial Demand VOWST commercial supply *Seres and Bacthera collaboration press release issued Nov. 10, 2021 + 10+ years of Seres technology & facility investment for anaerobic bacterial therapeutics Joint venture between Chr. Hansen and Lonza with offices in Switzerland
Slide 18: Company Profile: Leader in microbiome therapeutics
Company Profile: Leader in microbiome therapeutics with the first FDA approved orally administered microbiota-based therapeutic VOWST: Exceptional clinical profile meeting high unmet medical need and demonstrating early favorable adoption SER-155 Ongoing Phase 1b Study: Expanding proven novel techno
Slide 19: FDA Approval of VOWST and Clinical Data Support Continued Development of SER-155
FDA Approval of VOWST and Clinical Data Support the Continued Development of SER-155 in Medically Compromised Patients Including allo-HSCT VOWST SER-155 Phase 1b Cohort 1 data support broader infection opportunity in medically compromised patients; Cohort 2 clinical data expected Q3'24 Provides proo
Slide 20: Antimicrobial Resistant Infections - Urgent Public Health Threat
Antimicrobial Resistant Infections - Urgent Public Health Threat Limited innovation despite substantial and growing impact Declared “one of the world’s most urgent threats” $20 billion excess direct healthcare costs 35,000 deaths per year in US Major burden to society Many high-risk patient populati
Slide 21: SER-155 Designed to Modulate Targets Following Allo-HSCT
SER-155 Designed to Modulate Targets that Address Leading Causes of Mortality Following Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) Consortium of unique, human commensal bacterial strains Manufactured by cultivation from clonal cell banks and encapsulated for oral delivery Designed to
Slide 22: SER-155 May Represent a Novel Solution to Reduce GI Pathogen Abundance
SER-155 May Represent a Novel Solution to Reduce GI Pathogen Abundance and Infection & GvHD in Allogeneic HSCT | Seres Therapeutics, Inc. © 2024 SER-155 well-tolerated through 100 Days post-HSCT SER-155 bacterial strain engraftment was as expected GI pathogen domination was rare and transient in p
Slide 23: Pathogen Abundance Domination was Rare and Transient in Cohort 1
Pathogen Abundance Domination was Rare and Transient in Cohort 1 SER-155 Cohort 1 From HSCT Day 0-30, 11% of patients (1 subject, Fig.1 blue line) From HSCT day 0-100, 22% of patients (2 subjects, not shown) All instances of pathogen domination were transient Reference Patient Cohort (MSKCC; Peled e
Slide 24: SER-155 Potential Integration into Allogeneic HSCT Treatment Regimen
SER-155 Potential Integration into Allogeneic HSCT Treatment Regimen Unique potential clinical and economic value for allogeneic HSCT patients Double benefit of reducing GI associated infections, including BSIs, & acute GvHD, 2 of 3 leading causes of mortality at 1 year Avoids costs of post-transpla
Slide 25: Company Profile: Leader in microbiome therapeutics
Company Profile: Leader in microbiome therapeutics with the first FDA approved orally administered microbiota-based therapeutic VOWST: Exceptional clinical profile meeting high unmet medical need and demonstrating early favorable adoption SER-155 Ongoing Phase 1b Study: Expanding proven novel techno
Slide 26: Restructuring Prioritizes VOWST and Supports Longer-term Sustainability
Restructuring Prioritizes VOWST and Supports Longer-term Sustainability Before Strategic Restructuring 2024 – Anticipating $75 to $85 million in annual cash savings* Workforce - Reduced by 41% or ~160 positions across the organization R&D - Significantly scaled back all non-partnered programs and ac
Slide 27: Strategic Priorities | Compelling Path Forward
Strategic Priorities | Compelling Path Forward VOWST Commercial Growth SER-155 Phase 1b Clinical Results Financial Discipline Progressing commercial priorities to build upon VOWST launch momentum Focus on breadth of prescribing, utilization across the rCDI patient pool, and securing payer coverage p
Seres Therapeutics — Investor Presentation (January 2024) on 6ix